Chewy (CHWY) Down 10.3% Since Last Earnings Report: Can It Rebound?

Chewy’s fiscal Q2 2026 adjusted EPS was $0.36, in line with consensus, while sales rose 7.3% to $3.330 billion and beat estimates; adjusted EBITDA increased 23.7% to $226.7 million. Chewy raised its fiscal 2026 sales outlook to $13.46–$13.57 billion and lifted the low end of its adjusted EBITDA margin outlook by 10 basis points, but free cash flow fell 15.5% to $89.5 million and shares are down 10.3% since the report. The company repurchased $200 million of stock, completed its $400 million Modern Animal acquisition, and expects AI initiatives to deliver about $50 million in annualized savings in fiscal 2027; Zacks rates the shares #4 (Sell).

Analysis

CHWY: improving execution, but cash conversion is the test. The pullback alongside upward estimate revisions suggests price action may be discounting weak consumer demand and near-term momentum more than incremental guidance improvement. That is not yet a clear valuation opportunity: the article provides no multiple or price levels, so avoid assuming the selloff is overdone.

The key second-order issue is mix. Autoship supports retention, but recurring orders do not eliminate price sensitivity in easy-to-compare food and treat categories; persistent trade-down could limit revenue per customer and force promotions, pressuring gross margin. Health and pharmacy cross-sell could offset that over 6–18 months, but the growth case depends on profitable engagement, not just customer adds. Margin quality also merits scrutiny: timing and discrete items contributed to quarterly EBITDA, while free cash flow declined amid acquisition, investment and buybacks. If underlying cash conversion lags adjusted EBITDA, debt-funded capital returns could become less attractive.

Near term, weak momentum can persist into the next report despite modestly better estimates. Over 1–3 months, the catalysts are Q3 delivery against sales and margin guidance, organic customer spending, and evidence that cost savings recur. Longer term, automation and health expansion are potential margin levers, but company savings targets are not yet proof of realized earnings. Amazon and Walmart remain competitive constraints on price and convenience; share gains alone may not translate into pricing power.

Key Decisions for Investors

• Do not chase or short solely on the one-month decline. Put CHWY on a conditional long watchlist; initiate only after price stabilization and confirmation that organic sales/customer spending are holding up, with the next earnings report as the principal catalyst.
• Keep the thesis small until reported results separate recurring operating improvement from timing/discrete benefits. Verify free-cash-flow conversion, gross-margin trend, and realized AI/automation savings; a widening gap between adjusted EBITDA growth and cash generation would weaken the long case.
• Falsification: reconsider the long thesis if organic growth or net sales per active customer decelerates materially, promotions pressure gross margin, or Q3 sales/adjusted EBITDA fall short of company guidance. No price-based stop is specified because entry levels and current valuation are not provided.